Make Money in Profitable Small Caps the Easy Way

Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you expect small companies to do well in coming years as the global economy recovers, partly because they have so much room for growth due to their size, the iShares S&P SmallCap 600 Index ETF (NYSE: IJR  ) could save you a lot of trouble. Instead of trying to figure out which companies will perform best, you can use this ETF to invest in lots of them simultaneously.

The basics
ETFs often sport lower expense ratios than their mutual fund cousins. The iShares ETF's expense ratio -- its annual fee -- is a very low 0.20%.

This ETF has performed rather well, beating the S&P 500 over the past three, five, and 10 years, on average. As with most investments, of course, we can't expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver.

With a low turnover rate of 21%, this fund isn't frantically and frequently rejiggering its holdings, as many funds do.

What's in it?
Several of this ETF's components made strong contributions to its performance over the past year. Regeneron Pharmaceuticals (Nasdaq: REGN  ) , for example, gained 116%. The developer of a treatment for macular degeneration is seeing its future look brighter recently, as some of its rivals stumble. Questcor Pharmaceuticals (Nasdaq: QCOR  ) surged 231%, as its primary drug, one that treats multiple sclerosis, has been doing well, despite competition from a little outfit called Pfizer (NYSE: PFE  ) .

World Fuel Services (NYSE: INT  ) , meanwhile, gained 46% as its profits exploded recently -- though its cash flow didn't grow as spectacularly. Cubist Pharmaceuticals (Nasdaq: CBST  ) gained 55%, partly on the successful settlement of a dispute with Teva Pharmaceutical (Nasdaq: TEVA  ) that delays the debut of a generic version of a Cubist antibiotic.

Other companies didn't add quite as much to the ETF's returns last year, but could have an effect in the years to come. Piedmont Natural Gas, up just 13%, has been reporting solid operational results, but revenue slipped lately.

The big picture
A well-chosen ETF can grant you instant diversification across any industry or group of companies -- and make investing in and profiting from it that much easier.

Learn about the best dividend ETFs. And if you're looking for some great investments beyond ETFs, consider these 10 stocks for your retirement portfolio.

Longtime Fool contributor Selena Maranjian owns shares of Teva Pharmaceutical Industries, but she holds no other position in any company mentioned. Click here to see her holdings and a short bio. The Motley Fool owns shares of Teva Pharmaceutical. Motley Fool newsletter services have recommended buying shares of Piedmont Natural Gas, Teva Pharmaceutical, and Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1589650, ~/Articles/ArticleHandler.aspx, 8/30/2014 6:31:26 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement